NR1H4 and metabolic dysfunction-associated steatotic liver disease: FXR agonist obeticholic acid effectively reduced serum TG levels, alanine aminotransferase (ALT) and markers of liver fibrosis in patients with NAFLD and T2DM in a phase II study [126].